<SEC-DOCUMENT>0001564590-19-042154.txt : 20191108
<SEC-HEADER>0001564590-19-042154.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20191108140053
ACCESSION NUMBER:		0001564590-19-042154
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20191108
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191108
DATE AS OF CHANGE:		20191108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		191203499

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-8k_20191108.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-08T18:19:02.2844117+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 63f797e197a543a6b20d473869f2ccae -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20191108" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-8k_20191108.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20191108_20191108">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000921299_20191108_20191108">FIBROGEN INC</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20191108_20191108">0000921299</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20191108.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20191108_20191108">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-08</xbrli:startDate>
					<xbrli:endDate>2019-11-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20191108_20191108">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20191108_20191108" format="ixt:datemonthdayyearen">November 8, 2019</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.67%;"></td>
<td style="width:0.83%;"></td>
<td style="width:34.51%;"></td>
<td style="width:0.99%;"></td>
<td style="width:32%;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000921299_20191108_20191108">001-36740</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20191108_20191108">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20191108_20191108">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20191108_20191108">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20191108_20191108">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20191108_20191108">94158</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000921299_20191108_20191108">415</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20191108_20191108">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:35%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000921299_20191108_20191108">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style="width:30%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000921299_20191108_20191108">FGEN</ix:nonNumeric></p></td>
<td valign="top" style="width:35%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.33%;text-indent:-23.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20191108_20191108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:2pt;border-bottom:Double 2.25pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"><tr><td></td></tr></table></div>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_1"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.01</span></p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation FD Disclosure</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 8, 2019, FibroGen, Inc. (&#8220;FibroGen&#8221;) issued a press release announcing results from the pooled analyses of data from six global pivotal Phase 3 trials assessing the safety and efficacy of roxadustat as a treatment for anemia in chronic kidney disease compared to placebo in non-dialysis-dependent patients and to epoetin alfa in dialysis-dependent patients. The results were presented in a late breaker session at the American Society of Nephrology Kidney Week 2019 in Washington, D.C.&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of such press release is attached as Exhibit&#160;99.1 to this Current Report on Form 8-K and a copy of the presentation of the results will be posted on FibroGen&#8217;s website.</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item&#160;7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item&#160;7.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_2">Item&#160;9.01</p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.18%;"></td>
<td style="width:5.6%;"></td>
<td style="width:1.11%;"></td>
<td style="width:50.47%;"></td>
<td style="width:40.64%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex991_6.htm"><span style="text-decoration:underline;">Press Release titled &#8220;FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease&#8221; dated November 8, 2019</span></a></p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_3"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</span></p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:47.78%;"></td>
<td style="width:1.11%;"></td>
<td style="width:1.64%;"></td>
<td style="width:0.37%;"></td>
<td style="width:2.86%;"></td>
<td style="width:1.63%;"></td>
<td style="width:44.61%;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F<span style="font-size:9pt;">IBRO</span>G<span style="font-size:9pt;">EN</span>, I<span style="font-size:9pt;">NC</span>.</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: November 8, 2019</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.45pt;">
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqhynqe2gimc000001.jpg" title="" alt="" style="width:287px;height:78px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk22733128"></a>Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roxadustat did not increase risk of MACE and reduced risk of MACE+ compared to epoetin alfa in dialysis-dependent (DD) patients; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roxadustat reduced risk of MACE by 30% and MACE+ by 34% compared to epoetin alfa in the incident dialysis (ID) patient subgroup of the DD population</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roxadustat achieved primary efficacy endpoints in NDD and DD patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C., November 08, 2019 (GLOBAL NEWSWIRE) &#8211; FibroGen, Inc. (NASDAQ:FGEN), today announced results from the pooled analyses of data from six global pivotal Phase 3 trials investigating roxadustat, a first-in-class, orally-administered inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity. The pooled analyses assessed the safety and efficacy of roxadustat as a treatment for anemia in chronic kidney disease (CKD) compared to placebo in Non-Dialysis-Dependent (NDD) patients and to standard of care epoetin alfa in Dialysis-Dependent (DD) patients, including the clinically important Incident Dialysis (ID) patient subgroup. These Phase 3 trials conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., enrolled over 8,000 CKD patients from more than 50 countries. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;The pooled safety analyses assessing roxadustat as a treatment for anemia in chronic kidney disease demonstrate a cardiovascular safety profile comparable with placebo in patients not on dialysis, and comparable or in some cases better than that of epoetin alfa in patients on dialysis,&#8221; said Robert Provenzano, MD, Associate Professor of Medicine, Wayne State University, Detroit, Michigan, U.S. and a primary investigator on the global Phase 3 program. &#8220;It is exciting to see this application of the groundbreaking science on oxygen sensing and adaptation to hypoxia recently awarded the 2019 Nobel Prize in Physiology or Medicine, and </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">championed by FibroGen&#8217;s late founder and CEO, Tom Neff, who sadly passed away earlier this year. These positive safety results, coupled with roxadustat&#8217;s well-defined efficacy in CKD patients, and its oral formulation, support the potential for roxadustat to become an important new treatment option for patients with anemia associated with CKD.&#8221;&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These late-breaking data were featured in the High-Impact Clinical Trials oral abstract session on Friday, November 8, at the American Society of Nephrology Kidney Week 2019 in Washington, D.C. (Presentation FR-OR131)&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">+++</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pooled Efficacy Results&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individually, all six Phase 3 trials included in these pooled analyses (OLYMPUS, ANDES, ALPS, HIMALAYAS, SIERRAS, and ROCKIES) achieved the primary efficacy endpoint of mean hemoglobin (Hb) change from baseline compared to placebo in patients not on dialysis and to epoetin alfa in patients on dialysis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the pooled analysis of Non-Dialysis Dependent (NDD) patients (n=4277):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Roxadustat was statistically superior to placebo, demonstrating an improvement of 1.85 g/dL in patients&#8217; Hb levels from baseline to the average over 28-52 weeks compared to 0.13 g/dL among patients in the placebo arm, for an overall treatment difference of 1.72 g/dL (p&lt;0.001). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The rate of rescue therapy required in the first year of treatment among patients treated with roxadustat (8.9%) was less than one third of the rate of the placebo arm (31.1%) p&lt;0.0001; HR=0.19 (95% CI: 0.16, 0.23).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The rate of red blood cell (RBC) transfusions required in the first year of treatment was also lower with roxadustat (5.2%) than placebo (15.4%) p&lt;0.0001; HR=0.26 (95% CI: 0.21, 0.32).</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.29%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the pooled analysis of Dialysis Dependent (DD) patients (n=3880):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Roxadustat was statistically superior to epoetin alfa, demonstrating an improvement of 1.22 g/dL in patients&#8217; Hb levels from baseline to the average over 28-52 weeks compared to 0.99 g/dL, for an overall treatment difference of 0.23 g/dL (p&lt;0.0001). </font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">Roxadustat was superior to epoetin alfa across patients regardless of inflammation status, categorized by the baseline CRP levels (CRP &gt; 4.9 </font><font style="color:#000000;font-family:Times New Roman;">mg/L</font><font style="font-family:Times New Roman;">), demonstrating an improvement of 1.29 g/dL and 1.27 g/dL in Hb levels from baseline in patients with and without inflammation, respectively, compared to 0.96 g/dL and 1.05 g/dL with epoetin alfa.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.14%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The rate of RBC transfusions required in the first year of treatment was also lower with roxadustat (9.5%) than with epoetin alfa (12.8%) in DD patients (p=0.046). HR=0.82 (95% CI: 0.679, 0.997). </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Across the NDD and DD patient populations, roxadustat was effective in raising Hb levels regardless of whether patients were iron-replete (i.e., shown to have sufficient stores of iron in their body, TSAT% &#8805;20% and Ferritin &#8805;100 ng/mL) at baseline. NDD patients experienced a mean change of 1.94 g/dL from baseline with roxadustat in both iron-replete and non-replete subpopulations, compared to 0.13 g/dL in iron-replete and 0.33 g/dL in non-replete patients receiving placebo. </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pooled Safety Results </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Across these pooled safety analyses, the studies evaluated several different patient populations, including:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Non-Dialysis Dependent (NDD) patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Dialysis Dependent (DD) patients; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Incident Dialysis (ID) patients, who are patients who recently initiated dialysis (within 4 months). This ID subpopulation is the appropriate setting for comparison of roxadustat versus epoetin alfa, as this period of initial dialysis treatment is associated with substantially increased levels of safety events and patient mortality; whereas the stable DD patients have survived this period and thus are responsive to stable doses of erythropoiesis stimulating agents (ESA) such as epoetin alfa.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cardiovascular (CV) endpoints were defined as:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Time to first Major Adverse Cardiovascular Event (MACE): a composite endpoint of all-cause mortality, myocardial infarction, stroke;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Time to first MACE+, a composite endpoint which includes MACE plus unstable angina and heart failure requiring hospitalization; and </font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">Time to all-cause mortality </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">In the Non-Dialysis Dependent (NDD) patient population:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Risks of MACE, MACE+, and all-cause mortality in roxadustat patients were comparable to placebo in the ITT analyses based on a reference non-inferiority margin of 1.3. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqhynqe2gimc000002.jpg" title="" alt="" style="width:370px;height:245px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*ITT analysis agreed with the FDA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">In a post hoc subgroup analysis of 2,438 non-dialysis patients with baseline eGFR&#8805;15, </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The one-year decline in eGFR in roxadustat treated patients (-2.8) was significantly less than that in placebo treated patients (-4.4), with a treatment difference of 1.6 mL/min/1.73m2 (p&lt;0.0001).</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">In the Dialysis Dependent (DD) patient population:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Risks of MACE and all-cause mortality in roxadustat patients were not increased compared to those for patients receiving epoetin alfa based on a reference non-inferiority margin of 1.3.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Risk of MACE+ was 14% lower in roxadustat-treated patients than in those receiving epoetin alfa. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><img src="gqhynqe2gimc000003.jpg" title="" alt="" style="width:397px;height:203px;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;">&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">The Incident Dialysis (ID) patient sub-group of the Dialysis Dependent (DD) patient population:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Risk of MACE was 30% lower in roxadustat patients than in epoetin alfa patients, and risk of MACE+ was 34% lower.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Roxadustat-treated patients&#8217; risk showed a trend towards lower all-cause mortality relative to epoetin alfa-treated patients.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;<img src="gqhynqe2gimc000004.jpg" title="" alt="" style="width:405px;height:247px;"><font style="font-size:10pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>&#8220;The positive efficacy and cardiovascular safety results from these pooled analyses, in a population with a broad range in both CKD and anemia severity in over 8,000 patients across six Phase 3 global trials, reaffirm the potential of roxadustat to improve treatment for anemia in CKD patients.&#8221; said K. Peony Yu, MD, Chief Medical Officer, FibroGen. &#8220;There has not been much progress in treatment approaches for anemia in over 30 years, and more effective, safe, and convenient treatment options for patients are long overdue. We are privileged to be advancing </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this effort with roxadustat and plan to file the NDA in the U.S. by the end of this quarter for both dialysis and non-dialysis patients with our partner AstraZeneca and the MAA in Europe by the end of first quarter 2020 with our partner Astellas, followed by submissions to other regulatory authorities.&#8221;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+ + +</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Anemia Associated with CKD</font><font style="font-weight:normal;"><br />Anemia can be a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, a protein in red blood cells that carries oxygen to cells throughout the body. Anemia in CKD is associated with increased risk of hospitalization, cardiovascular complications and death, also frequently causing significant fatigue, cognitive dysfunction and reduced quality of life. Severe anemia is common in patients with CKD, cancer, myelodysplastic syndromes (MDS), inflammatory diseases, and other serious illnesses.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia is particularly prevalent in patients with CKD. The prevalence of CKD in the adult population is estimated at 10-12% globally and is generally a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure, or end stage renal disease, requiring dialysis or kidney transplant to survive. Blood transfusion is used for treating life-threatening severe anemia. However, blood transfusions reduce the patient&#8217;s opportunity for kidney transplant, increase risk of infections and the risk of complications such as heart failure and allergic reactions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the United States Renal Data System (USRDS), over 14% of the U.S. adult population is affected by CKD, and a majority of dialysis-eligible CKD patients are currently on dialysis. It is estimated that approximately 509,000 patients are receiving dialysis in the U.S. as of 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="text-decoration:underline;">About Roxadustat</font><font style="font-weight:normal;"><br />Roxadustat (FG-4592) is a first-in-class, orally administered small molecule HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and overcoming the negative impact of inflammation on hemoglobin syntheses and red blood cell production by downregulating hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis, increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease (CKD) patients, including in the presence of inflammation and without a need for supplemental intravenous iron. Roxadustat is currently approved in China for the treatment of anemia in CKD patients on dialysis and patients not on dialysis and approved in Japan for the treatment of anemia in CKD patients on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China, and other markets in the Americas and in Australia/New Zealand as well as Southeast Asia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About&#160;FibroGen</font><font style="font-weight:normal;"><br />FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#8217;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), is approved by the National Medical Products Administration (NMPA) in China for CKD patients on dialysis and not on dialysis and by the Ministry of Health, Labour and Welfare in Japan for CKD patients on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit </font><font style="text-decoration:underline;color:#0000FF;font-weight:normal;">www.fibrogen.com</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="text-decoration:underline;">Forward-Looking Statements</font><font style="font-weight:normal;"><br /></font><font style="font-style:italic;font-weight:normal;">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of roxadustat, our interpretation of the pooled safety analyses and other analyses of the global Phase 3 program for roxadustat, , the potential for and timing of an NDA submission to the FDA and an MAA submission to the EMA for potential marketing approval for roxadustat, the potential safety and efficacy profile of our product candidates, aspects of roxadustat that could affect its commercial prospects, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;will&#8221;, &#8220;should,&#8221; &#8220;on track,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:normal;">&#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Inquiries: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sara Iacovino </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.703.474.4452</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#0000FF;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">sara.iacovino@gcihealth.com</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Tung, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.415.978.1433</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#0000FF;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ir@fibrogen.com</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gqhynqe2gimc000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqhynqe2gimc000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, 8X# 2(  A$! Q$!_\0
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MW=EMV"3_  AL C-:W@[7[W79?$*W@B T_6)[*'RU(S&FW&>3D\]:P3\(]/\
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M[&ZL=0MIH+6:[59D0&6.($MA0Q*G R P7-.T[XB:=J3R1QZ9JL<PT]=2@A>
M;[B!B &0!CW(&#CUZ<UA67P@ALF^76I'46MW:*3:('*S@@L[CEW!/4^F,"KN
MH?"VWU"WCA?5[F,)H4>C QQ@$A)%<2'GN5P5Z$$T 0ZA\2_/ALQI%NT=TNN6
MNFWMO=*K,JRY/RE'*Y('!R<'K6JGQ)T1K"QO/*O%CNK>ZN74Q#=;I;Y\PR '
M@@C: ,Y-9EM\*XX)O.?5\N=4M-2816:1)O@! 154X52"/ICO2^%?!EU;Z_XH
MUFZAETXZDS1V4+21RM;HWS2,!\R?/)\VWGIS0 _5/B)O\'7.M:?:W-F(Y+<1
MS74"RQRK(ZK\NR3!.#R,@CN*V;#QO8ZGXAN=(L[*^F-M</;37*(ACCD7J&&[
M>!VW%<$]ZYS_ (5);O8:I ^JB.34#!O^RV:01+Y4@?=Y2G!<D8+?I6K/\/TN
M_&-OX@GU$;K>X^T1B*TCBF/&!&\RX+Q^Q&?4T =I1110 4444 %%%% !1110
M 55U)BNE7C*2&$#D$'D?*:M4V2-)8GCD4,CJ58'N#UH \,T19]%\->!O$-GK
M6IRZGJ=]!;75K/>M+'<1R$A_D8G!  .1TJM;_:=,^']MXPM=;U0ZVNJF)8'O
M6>.X7[28_+\LG!&WTYXKUG1_A]X3T#4%O],T*UM[I 0DH!9ESZ9)Q^%-L?AU
MX0TW5%U.TT&TCO$?>LI!8JWJ 20#[T 5O%U]<?\ "4^$-&BEDBAO;V2:=HV(
MW+#&7"$CL6VY'?%>/:=/K3WFG2^;J5G+?:U)!;ZS-J[M -LIS&T&" 2H*@$X
M->]:WH*:Q<Z5="8P7.FW:W,4@7=D8*NA]F5B/;@]J9)X2T&71'T9],A;3WE,
MS0'.-Y;<6!SD'//!H \VD3^W['Q=K^I>)M1T_4-*O+F*VAAO##':+%_J\Q]&
MW8R2?O9XIVD7%UX]U6.W\1:O?::L&B6EW';VER;;S7E5C),<<G! &.@S7H&H
M^!?"VKZFFHZAH=G<WB8_>R)DMCIN_O?CFIM<\(>'O$OD?VQI-M>& 8B:1>5'
MH".<>W2@#RSQ)K/B'1]?LXO"]]<:_(?#<I%R9E<8$O,Y ^5W &T=R2.M7)[F
M"WA\*'1=7O[FRN=)U*=KB:X9GF?R0=S\_>!SQ_">!7I]KX>TBQO8+RTT^"">
MWMOLD31KM"0YW; !QC/-5(/!?ARUV>1I4*!#,4 +87SAB3 SP& Y H \Q^']
MIJB:;9:W?6>H6T0TYYSJLVO-<IDQ'YS;?CG'.*G\#SWFE>)]$74M1OYCJL,H
MCNH]3^UVNH,%W[]C8:$@9(X]J[W2_ASX0T348M0TW0[>WNXL[)%9B1D$'J<=
M"14MCX#\+Z5=7-WIVB65M=3QLC2+'T##! &> ?08H S_ (JW,UK\,-;N+6>2
M&9(D*21.58?O%Z$<BN#\2:_XGFU:]&I:?+HIC\+WTD4<.HB82, ,2?+C##MW
MKU2W\*Z8GA&#PU=0"ZT^.!(6CDX#A<$9Q[C-3W_AS2-3F,U[8QS2&U>S+,3_
M *E_O)UZ&@#Q"X\5:IX<\;ZAJ[WMW+91Z?:VGD-(S)YTMF'C.,X!+QXS_M&I
MK'6K_1OAQ=Z+?ZIJ$E_=>(7TY[F-GEGCB38960#+<*"..[5[!)X-\.S&8R:3
M QF:!Y,Y^8PC;$>O\(X%36_A?1+35/[3@T^)+WS)9?.&<AY<>8W7&6VC/TH
M\LT[Q/<ZAX/\*P&^N_M5AXHM]/N))"T<DT8WE"X/.&0KD'J0:Z_XI:\NF^'+
M:PBN;B&;5+M+8RVBL\L<6=TKH%Y)" CCU%;FI^"?#>LO=OJ&DPSM>21R7!8L
M/,:-2J$X/4 D?C3-'\"^&- NHKK2](@MIHMYC=2Q*[P V,D]0H'X4 >8V7B+
M4$\ P>)K2]N9M0\*W$EK=P7+O']MMB<*74\AMK(P)&<@U#XOGU+2=+TS0)]:
MU,:O=QS:OJ%S9"25A*5(BC4+DK%O.,<#">]>OW/A?1+QM3:XTZ)SJBHM[DD>
M>$&%W<]A5J#2;"VU*XU&&V5+RXC2*67)RRIG:/8#)Z4 >5ZQJ]YXUT_PM<6%
MZSO<6<D]SI$.H-8R3.,*S+*!@[&#?*2/6NX^'FIIJ?@RRD^V7EU)&TD+R7NT
MR[D<@ABIPV.FX=<9J:[\!>%K^Q^Q76B6LMOY[W 1@?ED<Y8@YR,]P.*FA\)Z
M9::II5W9V\5K'ID$L-O#"FT 28S^''IU.<T >>^/1?W/BO4IK?4KJXM].LT=
M[6QU,V<U@<%C+L8;)@1CC/;%8OBG7KR[TKQ'=V6I7SQRZ9H\L#^:86/F2<G
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M>N[^/&,]Z]1U'PIH.KZE%J%_I=O<7<84"1UZA3E0PZ, >0#G%'_")Z!_;O\
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M /HF76=-@U:#2I;^W34)T+Q6S2 2.HSDA>I'!_(U%JWB+1=",8U;5;.Q,O\
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M7OI8?1116AQ!1110 4444 %%%% &'JGB_1-&U_3M$OKORK_4#BWCV$[N<#)
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MDTOX@:'JT,$L)NXHYK[^SU:XMFC_ '^TML.>G3'UXH ZFBBB@ HHHH ****
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M_P#&Z[>B@#E_#/A.[\/ZMJ-Y<^(=0U9+N.)$6]8%HMF[.",#G=Z#IWKJ***
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MIK#Q%)JGFC:]HMOY>WH0[-G/_ JT**+%*35[=3DO$7@Z;7;V[E-W;^5<VP@
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+@VX]0HHHK,T/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gqhynqe2gimc000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqhynqe2gimc000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V 7,# 2(  A$! Q$!_\0
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M'$JW5N!X@M8X;<'=^Z*Q%"7XZ9.>*Q;WX8ZI<Z1X@LUOK,/J6F6%E&QW85H
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M1X&XR3*"RG)(/H<5VVEZU=_\+%U;0[BX$UO)8P:A:  ?NU)*.H(ZC< 1GU-
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MN&G^RI*@CRS[F&-O0DG\Z6[^%>FW=[.3J^KII5Q<_:IM)2X_T=Y,[CQC(!8
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M$ZS$R[K<G=YBX 4':Q&"<8YJ[XPMIHO%W@W5UC9X+:]EMIMJD[!-&55CZ#<
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MDDCZ<T >AT5\Q_#WXL>,I_&5RDMK<ZZM^6D>RB.#$0.#'GA !@$'@_6O8/\
MA.O$O_1.M8_\"(?\: .\HK@_^$Z\2_\ 1.M8_P# B'_&L[7?B9XCTC2);U_
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M R <'//2@#JZ*@BO+6XGG@AN(9)K<A9HT<%HR1D!@.F1SS4] !1110 4444
M%%%% !112$A02Q  ZDT +1110!CZ9_R,.N?[\/\ Z+%;%8^F?\C#KG^_#_Z+
M%36'B#2-4U*]TZQU"">\L6"W,*-EHR?7^7'?B@#2HHHH **3< 0"1D]!ZTM
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M_?A_]%BMB@#@_P#A!/$?_11=:_[\Q?X4?\()XC_Z*+K7_?F+_"N\HH X'3_
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MNYJUK?PV&JW^M7$&NW=C%K<"17\,42,)"B[58$C*\=0.M2WGQ&MM)TRVGO\
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MOH=4N(&,8PBA& VKQ]T<XSS7,V7BS6_[;M-8FU"1[*\U^XTDZ=L7RXXD5MC
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M4;&(6<UK:M&(KRSA$:3$KR" 2"RX&2#W'0@T =/1110 4444 %%%% !1110
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M-YB[EVCV[_2@"Y'(DJ!XW5T/1E.0:=7+^!TB_LV\NHC;QB\NWN1:P2*RVP8
M!#M. Q W,!W8UU% !1110 4444 %%%% !61K7BC1?#K0KJU^EJ9@3&&5CNQC
M/0'U%:]<%XQL+^_\=^&XM.O38S>1=?Z2;<3!>%X*MQS43;2NCHPM.%2IRS=E
M9O[E?L_R.RTS5++6;".^T^X6>UDSLD4$ X.#U]Q5H@$$$9!Z@UY=XYFOK*&V
MTR2YO);U-/DD2\C>2".24'HL<(^:3T!(4>],OIM<DDTNUM[B\9?$EE:K).'8
M?9Y$P96']W<A[8YJ/:VTL=*P/,E)2LG>WHO^!=[+;8]4VKC&!C&,8H50HPH
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EQTJU113;;W$DD%%%%(84444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gqhynqe2gimc000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqhynqe2gimc000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ 2 # 2(  A$! Q$!_\0
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M/(7*C;VS5_Q+HT?A[X0WVE0S/-';V^T.X )S)GG'UK&^"/\ R#-8_P"OA/\
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M,4M[;HX]00F17O\ T&!2E+E2L@2NV>'>$_'>N>'O$::/XAFGEMVE$,JW)S)
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I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gqhynqe2gimc000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqhynqe2gimc000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X 98# 2(  A$! Q$!_\0
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MR;A=DD>1T89X->*>%/#FN:<VK01Z5=FWET2>"22:T-M)YN#M0@,4G<G_ ):
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M&!D]^*DHH 9YB^<(N=Q4MTXQ_DT^JY_Y"*?]<6_F*L4 %%%% !1110 4444
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MH6IZ]]JF:[%VZ-!J,TI:=T"X$<@Z?(<X(Z@^M &K)XKT"*:UBDU>S62ZD:*
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MY_SVO/\ P F_^)KJZ*+3[_A_P0Y\-_(__ E_\B<I_P +&\.?\]KS_P  )O\
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M^1,_5/\ C^T;_K\/_HF6M.LS5/\ C^T;_K\/_HF6M.K.4**** "BBB@"N?\
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M^OP_^B9:TZ "BBB@ HHHH KG/]H)UQY3?S%6*K'_ )"2=,^2W\Q5F@ HHHH
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M9^4 CWR?I0!<N/'D]WHWAUM!L8;G5->1FMXKB4I%%L7=*7(!/R],#G-4-?\
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M?)92*#%&QZG'<>@/ _+$R]KI:QO26!M+VCE>VFVYU']NZ/\ ]!6Q_P# A/\
M&C^W='_Z"MC_ .!"?XU3_P"$-\,?]"_IG_@*G^%'_"&^&/\ H7],_P# 5/\
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M %^'_P!$RUITR0HHHH **** *YS_ &@G7'E-_,58JN?^0DG3_4M_,58H 0D
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MP2=T64RO(LP'\:E^=I_H:W:**T2LK'-4ESR<EU"BBBF0%%%% !1110 4444
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MI"B$],MG S[UI*ZNBNC!E89# Y!% "T444 %%%% !1110 4444 %%%% '/\
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M]W/;KK=DK0XW,\H1#G/W6/#=.U)R2W9I"E4FFX1;L=%16-_PEWAO_H8-+_\
M R/_ !H_X2[PW_T,&E_^!D?^-+FCW'["K_*_N9LT5C?\)=X;_P"A@TO_ ,#(
M_P#&C_A+O#?_ $,&E_\ @9'_ (T<T>X>PJ_RO[F;-%8W_"7>&_\ H8-+_P#
MR/\ QH_X2[PW_P!#!I?_ (&1_P"-'-'N'L*O\K^YFS16-_PEWAO_ *&#2_\
MP,C_ ,:/^$N\-_\ 0P:7_P"!D?\ C1S1[A["K_*_N9LT5C?\)=X;_P"A@TO_
M ,#(_P#&C_A+O#?_ $,&E_\ @9'_ (T<T>X>PJ_RO[F;-%8W_"7>&_\ H8-+
M_P# R/\ QH_X2[PW_P!#!I?_ (&1_P"-'-'N'L*O\K^YFS16-_PEWAO_ *&#
M2_\ P,C_ ,:/^$N\-_\ 0P:7_P"!D?\ C1S1[A["K_*_N9LT5C?\)=X;_P"A
M@TO_ ,#(_P#&C_A+O#?_ $,&E_\ @9'_ (T<T>X>PJ_RO[F;-%8W_"7>&_\
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MHR(QM[V^LC8O=+EBL7/ 4G&?F;GWK3M+6*QLH+2W7;#!&L4:^BJ, ?D*FHH
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M6/<8X)'O6_10!B7.CW5X;6.9[)((3&Y\J AU9"#A&S\HX';IFMNBB@ HHHH
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MV=W::;?)))<RLL;R;H\[VR?NJ<X'3-6\/-*Y/M8WL='1116!J%%%% !1110
M4444 %%%% !1110 4444 %%%% $-W;+>6<]L[.J31M&S(<$ C''O5*XT*SN?
M#XT1_,%H(EB&&PP"XQSZ\"BBDTGN5&<H[/S*$G@W3IM.O+.::ZE6[F6:61G
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5],_KQ113]K/N+V<>QM4445F6?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fgen-20191108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-07T18:53:31.6219536+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 63f797e197a543a6b20d473869f2ccae -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:fgen="http://www.fibrogen.com/20191108" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20191108" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20191108/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fgen-20191108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-07T18:53:31.6219536+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 63f797e197a543a6b20d473869f2ccae -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>fgen-20191108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-07T18:53:31.6219536+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 63f797e197a543a6b20d473869f2ccae -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20191108/role/TemplateLink" xlink:href="fgen-20191108.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20191108.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6624870880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 08, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  08,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>fgen-8k_20191108_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20191108.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20191108_20191108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2019-11-08</startDate>
            <endDate>2019-11-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000921299_20191108_20191108" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0000921299_20191108_20191108" id="F_000003">FIBROGEN INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20191108_20191108" id="F_000004">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000921299_20191108_20191108" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20191108_20191108" id="F_000002">2019-11-08</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20191108_20191108" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000921299_20191108_20191108" id="F_000006">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20191108_20191108" id="F_000008">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20191108_20191108" id="F_000009">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20191108_20191108" id="F_000010">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20191108_20191108" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20191108_20191108" id="F_000012">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20191108_20191108" id="F_000013">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20191108_20191108" id="F_000014">978-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000921299_20191108_20191108" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000921299_20191108_20191108" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000921299_20191108_20191108" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000921299_20191108_20191108" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000921299_20191108_20191108" id="F_000019">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20191108_20191108" id="F_000020">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20191108_20191108" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20191108_20191108" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%G;>V*W]Q\8GP:Z%7W?1?0%02P,$%     @ &G!H3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<ZV200J#,!  OR)Y0%=MZ:&HIUZ\MOU
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M2NU!7PW_R?(+4$L! A0#%     @ &G!H3Q\CSP/     $P(   L
M     ( !     %]R96QS+RYR96QS4$L! A0#%     @ &G!H3R?HAPZ"
ML0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  :<&A/N.TTS.\    K @  $0              @ &9 0  9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  :<&A/F5R<(Q &  "<)P  $P
M        @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !IP
M:$^=DA&QH0(  ),+   8              "  ?@(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  :<&A/&#W7V5D"    !@  %
M        @ '/"P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  :
M<&A/NJ$YBM<!   R!@  #0              @ %:#@  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( !IP:$\6;2-_0P$  #P"   /              "  5P0
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  :<&A/_\ F"+T   "% @
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  :<&A/"X_8 R$!  !7!   $P              @ '!$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "@ * ( "   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-19-042154-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-042154-xbrl.zip
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M%#>GO,'$F"E]^?+*JUW>>LYI)^6+()8\D)L,!XK)5UR8$^19N9>%=@4$096
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M^GX-1J.4X87JO^-6P.H*W@"(? V(]J5WVY<6RZ9E]["O;0G$MN!ZX6][\;-
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M=*/@B>/DRM,SKF_=^)W">4?YS;(<&-AUGG&Z$L%TNH5G92616GBJR<9+X@.
MM%*MP_?*$RIU:#63_>_'5:'0]+C[T>,^]=<:5^/#5PEY?OI)N$Y9NMP4&&V>
MV/]O6/R9*62;.Y7]?&E0>2;=9XK]^UGLI_(S<B1HM80L!H4Z4-/7+&5;)U[[
M7&^?LI?!?JTM=^HUN=@J7HSK_P!02P,$%     @ &G!H3_;I*%$G!P  F4D
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MVET9V7G3UT>&CC;G**M62J7'R(8'>7.YSUHV6\,G')#"3T*V^U5<@S=PS)=
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M":>NUG.J1B9.U5,04'4JV-?M% _^^V$7#1CV+T98!/'V "E2P99V<C!D:!8
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M7[Q@M./CHJ0I)OMUL)26?V'EW#A'K$"?]FQ>&]U<,?_,JY0?_@%02P,$%
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M'>Y>,-= U"IH>!Z9NXHH2768(E1&UL+1.IMI"73?!HV?&4?-Z*B/WDLLENC
M[1_['-Y,1$*J5ORL^IM$Y-OLI=>0PT]-//OIBLAB;7PJYR42^",KW]&<=,V4
M!U 6@3K:@;#OC\A_FX9I$9]*)('A.F<I%O/D5<CD#03LGDQFR20_E; 3,>^0
M=Z]Y*]&7J^;+26%-CK$"]W\%M>PJ*5AI'",V^-:^IVK.9D=!$Q_$N@-KHDF5
M0_\B7US1P5L>F0LF!_E.Y7UZ(MU[V93/2]EG;PGYL&9LPW/0!0!FU8C8.NX,
M$[\'-8#ITQ8S06&N"/4( Y3T4,/K2?$8]-&3X&.@F"KBL"[WPJ/"8;#'+*7<
MA#"Y *% #A"@Y1,=\(DK<WW(V,=#QI@6$?K$\YUL?L5;%<:=HE=BTB[1[5P*
M[#;23)*)Y M&H?#KU"RRT;NMH:6K=+H(5[_\_Z=@QGLQ8):Y-I?E^);F4RWC
M*7W1,ZJ'$_HYCD=<T5S*VC:2V=:RINX29H/Y<*F<B\]ELO2!+VG1 GS)$]JW
M-51,UX+)1/DR.".N_5WA97*(=CV6.\+!'SD,C3S.@^5"B60/7$&[[OB.8FKK
M6U.Q,EXDZE#IJ#!3QEGD6"L<T+%C+<G&C#?>,6,278$DYY/$EEYT]W)R.MYP
MAD^\_%"O0QX;N?U>Z&1<T;&(UC-HPJ$NHS69.3VF/XXZ^;3'LAW)Z'V6=D%L
MU:C[2$<JNH-U<XMX56BL^@Y),'-^E(UDK6I9!%9Q\,/ZD?]A ;+G]NC&YWC>
M"-@@W ME,.(3/&'E,)GU:1%XWF*]H1MF1%Y?DLFM_"^P/G#MU6?33DM;)&]O
M\'S<],571V3ZX!@JUI5\WCR)7^M'Z^00+ ,U!#E'0>3A40T) I>"D*6>!U(1
MV0Z\4D,W4*0KQ4"+/!\4*6SB47>DF#[>X=" AA44?R*]T"[T^8,(X.]M'WLL
M@*P&>0N&B()&"GO&SA3ML@!,$,\A#,^#4%LGKDKQ1)TAW@*"U@F%MHP&.OR)
M\IUZ;, I&BMV7PH/M,E[[GAL1!P0[CB85C9DF$_KN]1F'8&U\=YVA^.TN<HZ
MS&<:F<0'RH&_2L\"6C!?,% ("'6[>I E30QRIY66$$2/3#(-2/0V:&.*$E>K
M.B@+\")?IH\8$UB6CLIIG1-835O8',$ *V\R'];DBMZ(? T7]0=C]^$W%J##
MV=LYG\VA_EBT? &H\S4<U-#NSQ E6K%!0$%I=) JKI[ZO,.#$ +5JF$A[K2U
M6-?WYP?Q'7;(%>*<:T0Q'0^BR3G$UTP^=810[KJD@R2O$*'846(#Z0,?CZP#
M"BA;9)A^/!0@07-O?$T]$IT&ZK0 0F1T&.[B[E!Z7 %.CK26WN4N_IQ*2TAR
M9P,T91O4%6CJ@C40S(\V,U#L @B/3X0HP8$Z+'&S B 'S(GQ3=V84"^TWA_;
M$[IS?:M0R$5PEM@$QX_,R\79K9'/XTCSHH&V/(Z@MHO$&5VS9H-E.2+C:[<=
M[$8RY  QG*8F&Y<F)QWRD@B<.L^_FP:>)##@%X(B<7S@2%.X(Y@N.4*+68%!
M/00F1(G#0!D=@.D3TCJ>6(DN/9@%1="/6-3RP<>ID+'1!0,<X8-N'W[&0T@
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MT9G0JN[2879T-VY-.V#Q<ZGAN3>%GXD.7?_ZNZ0.F8EBD8LP3 6+N168!O+
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MJ_VHHJO>YZQ+OK$>=<D-GD9D\N<<P9D]@7.:ZPAGI ?K!P,7?OP;4$L#!!0
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MFS*XD)-LRS@..FUH\84K.-%?ROOTF*!#UXN&/F([O)$,$PCEM$)A9K.VE8F
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M7I'E41X&^./_ 5!+ 0(4 Q0    ( !IP:$\N"?S_T00  'X7   1
M      "  0    !F9V5N+3(P,3DQ,3 X+GAS9%!+ 0(4 Q0    ( !IP:$_V
MZ2A1)P<  )E)   5              "  0 %  !F9V5N+3(P,3DQ,3 X7VQA
M8BYX;6Q02P$"% ,4    "  :<&A/6$"L\@ %  #>*P  %0
M@ %:#   9F=E;BTR,#$Y,3$P.%]P<F4N>&UL4$L! A0#%     @ &G!H3TNX
M8Z12$P  #K4  !0              ( !C1$  &9G96XM.&M?,C Q.3$Q,#@N
M:'1M4$L! A0#%     @ &G!H3P1;K@SQ'0  X],  !               ( !
J$24  &9G96XM97@Y.3%?-BYH=&U02P4&      4 !0!% 0  ,$,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-8k_20191108.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-8k_20191108.htm">fgen-8k_20191108.htm</File>
    <File>fgen-20191108.xsd</File>
    <File>fgen-20191108_lab.xml</File>
    <File>fgen-20191108_pre.xml</File>
    <File>fgen-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-8k_20191108.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-8k_20191108.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20191108_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20191108_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20191108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20191108",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191108.htm",
      "contextRef": "C_0000921299_20191108_20191108",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191108.htm",
      "contextRef": "C_0000921299_20191108_20191108",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
